Increase in dopapositive melanocytes in the mouse intestine in response to ultraviolet B rays via the eyes

Clinical and Experimental Dermatology

Volumn 36, Issue 1, 2011, Pages 52-56

  Hiramoto, K ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; DOPA; MELANOCORTIN 1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLON; CONTROLLED STUDY; EAR; EPIDERMIS; EYE; HORMONE BLOOD LEVEL; JEJUNUM; MALE; MELANOCYTE; MOUSE; NONHUMAN; PIGMENTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION EXPOSURE; RADIATION RESPONSE; SKIN PIGMENTATION; ULTRAVIOLET B RADIATION; ANALYSIS OF VARIANCE; ANIMAL; DBA MOUSE; INTESTINE; METABOLISM; ULTRAVIOLET RADIATION;

ANALYSIS OF VARIANCE; ANIMALS; DIHYDROXYPHENYLALANINE; EAR; EYE; INTESTINES; MALE; MELANOCYTES; MICE; MICE, INBRED DBA; RECEPTOR, MELANOCORTIN, TYPE 1; ULTRAVIOLET RAYS;

EID: 78650166488     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2010.03777.x     Document Type: Article

References (17)

1. Mouret S, Baudouin C, Charveron M et al. Cyclobutane pyrimidine dimmers are predominant DNA lesions in whole human skin exposed to UVA radiation. Proc Natl Acad Sci USA 2006; 103: 13765-70.
2. Lin JY, Fisher DE. Melanocyte biology and skin pigmentation. Nature 2007; 445: 843-50.
3. CarioAndre M, Bessou S, Gontier E et al. The reconstructed epidermis with melanocytes: a new tool to study pigmentation and photoprotection. Cell Moll Biol (Noisy-le-Grand) 1999; 45: 931-42.
4. Jimbow K, Uesugi T. New melanogenesis and photobiological processes in activation and proliferation of precursor melanocytes from Langerhans cells. J Invest Dermatol 1982; 78: 108-15.
5. Rorsman H, Tegner E. Biochemical observations in UVinduced pigmentation. Photodermatol 1988; 5: 30-8.
6. Hiramoto K, Jikumaru M, Yamate Y et al. Ultraviolet A irradiation of the eye induces immunomodulation of skin and intestine in mice via hypothalomopituitaryadrenal pathways. Arch Dermatol Res 2009; 301: 239-44.
7. Millington GWM. The role of proopiomelanocortin (POMC) neurons in feeding behaviour. Nutr Metab 2007; 4: 18-33.
8. Millington GWM. Proopiomelanocortin (POMC): the cutaneous roles of its melanocortin products and receptors. Clin Exp Dermatol 2006; 31: 407-12.
9. Hiramoto K, Yanagihara N, Sato EF et al. Ultraviolet B irradiation of the eye activates a nitric oxidedependent hypothalamopituitary proopiomelanocortin pathway and modulates functions of αmelanocytestimulating hormoneresponsive cells. J Invest Dermatol 2003; 120: 123-7.
10. Hunt G. Melanocytestimulating hormone: a regulator of human melanocyte physiology. Pathobiolgy 1995; 63: 12-21.
11. Lu D, Chen W, Cone RD. Regulation of melanogenesis by the MSH receptor. In: Pigmentary System, Physiology and Pathophysiology (Nordlund JJ, Boissy R, Hearing VJ et al. eds). Oxford and New York: Oxford University Press, 1998; 183-96.
12. Rees JL, Healy E. Melanocortin receptors, red hair, and skin cancer. J Investig Dermatol Symp Proc 1997; 2: 94-8.
13. Chakraborty AK, Funasaka Y, Slominski A et al. Production and release of proopiomelanocortin (POMC) derived peptides by human melanocytes and kelatinocytes in culture: regulation by ultraviolet B. Biochem Biophys Acta 1996; 1313: 130-8.
14. Chakraborty AK, Slominski A, Ermak G et al. Ultraviolet B and melanocytestimulating hormone (MSH) stimulate mRNA production of αMSH receptors and proopiomelanocortinderived peptides in mouse melanoma cells and transformed keratinocytes. J Invest Dermatol 1995; 105: 655-9.
15. Pawelek J, Chakraborty AK, Osber MP et al. Molecular cascade in UVinduced melanogenesis: a central role for melanotropins? Pigment Cell Res 1992; 5: 348-56.
16. Schmidt LD, Xie Y, Lyte M et al. Autonomic neurotransmitters modulate immunoglobulin A secretion in porcine colonic mucosa. J Neuroimmunol 2007; 185: 20-8.
17. Brzoska T, Luger TA, Maaser C et al. Alphamelanocytestimulationg hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immunemediated inflammatory diseases. Endocr Rev 2008; 29: 581-602.